CompletedPhase 3

Osteoporosis Prevention With Low Dose Alendronate

Belgium83 participantsStarted 2007-09

Plain-language summary

The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic patients, who don't want or can't receive an oestrogenic substitution treatment.

Who can participate

Age range45 Years – 60 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 45 to 60 year-old women * Menopausal since at least 6 months * Baseline lumbar BMD from -1 till -2.5 Exclusion Criteria: * Bone disease other than osteopenia * Treatment with selective estrogen receptor modulator (SERMs), calcitonin or hormone replacement therapy within 6 monts prior to randomization * Former or current treatment with any bisphosphonate or bone forming agents * Chronic use of oral or iv corticosteroids * Any diagnosis of malignancy less than 12 months

What they're measuring

percentage of lumbar BMD modification after 2 years

Timeframe: 2 years

Trial details

NCT IDNCT00463268

SponsorUniversity Hospital of Mont-Godinne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-01

View on ClinicalTrials.gov More Osteopenia trials